2,3-dihydro-2,3-dihydroxyaflatoxin B(1): acid hydrolysis product of RNA-aflatoxin B(1) adduct formed by liver microsomes; structure; RN given refers to (6aS-(6aalpha,8beta,9alpha,9aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3035008 |
| CHEBI ID | 82580 |
| MeSH ID | M0050583 |
| Synonym |
|---|
| aflatoxin b1-2,3-diol |
| 50668-79-6 |
| C19588 |
| aflatoxin b1-2,3-dihydrodiol |
| aflatoxin b1 diol |
| unii-p8e807ja4n |
| cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,8,9,9a-hexahydro-8,9-dihydroxy-4-methoxy-, (6as-(6aalpha,8beta,9alpha,9aalpha))- |
| 2,3-dihydro-2,3-dihydroxyaflatoxin b(1) |
| cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,8,9,9a-hexahydro-8,9-dihydroxy-4-methoxy-, (6as,8r,9r,9ar)- |
| p8e807ja4n , |
| 2,3-dihydroxy-2,3-dihydroaflatoxin b1 |
| cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,8,9,9a-hexahydro-8,9-dihydroxy-4-methoxy-, labeled with carbon-14, (6as-(6aalpha,8beta,9alpha,9aalpha))- |
| CHEBI:82580 |
| cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,8,9,9a-hexahydro-8,9-dihydroxy-4-methoxy-, (6as-(6a.alpha.,8.beta.,9.alpha.,9a.alpha.))- |
| 2,3-dihydro-2,3-dihydroxyaflatoxin b1 |
| 8,9-dihydroxyaflatoxin b1 |
| Q27156099 |
| DTXSID30964904 |
| 8,9-dihydroxy-4-methoxy-2,3,6a,8,9,9a-hexahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h][1]benzopyran-1,11-dione |
| (3r,4r,5r,7s)-4,5-dihydroxy-11-methoxy-6,8,19-trioxapentacyclo[10.7.0.02,9.03,7.013,17]nonadeca-1,9,11,13(17)-tetraene-16,18-dione |
| Excerpt | Reference | Relevance |
|---|---|---|
| " These results suggest that AFAR activity is related to resistance to the acute toxic effects of AFB1 only in chickens and ducks." | ( Dealing with aflatoxin B1 dihydrodiol acute effects: Impact of aflatoxin B1-aldehyde reductase enzyme activity in poultry species tolerant to AFB1 toxic effects. Diaz, GJ; Murcia, H, 2020) | 0.56 |
| Class | Description |
|---|---|
| coumarins | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||